Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study

Item

http://www.wikidata.org/entity/Q59284818

description

im Februar 2012 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 February 2012

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2012

@uk

name

Evaluation of Eslicarbazepine ...... ion in a Thorough QT/QTc Study

@en

Evaluation of Eslicarbazepine ...... ion in a Thorough QT/QTc Study

@nl

type

Item

label

Evaluation of Eslicarbazepine ...... ion in a Thorough QT/QTc Study

@en

Evaluation of Eslicarbazepine ...... ion in a Thorough QT/QTc Study

@nl

prefLabel

Evaluation of Eslicarbazepine ...... ion in a Thorough QT/QTc Study

@en

Evaluation of Eslicarbazepine ...... ion in a Thorough QT/QTc Study

@nl

P1476

Evaluation of Eslicarbazepine ...... ion in a thorough QT/QTc study

@en

P2093

Jeffrey S Litwin

http://www.w3.org/2001/XMLSchema#string

Manuel Vaz-Da-Silva

http://www.w3.org/2001/XMLSchema#string

Maria J Gutierrez

http://www.w3.org/2001/XMLSchema#string

Teresa Nunes

http://www.w3.org/2001/XMLSchema#string

P2860

Risk factors in sudden death in epilepsy (SUDEP): the quest for mechanisms.

Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers.

Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy.

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.

Moxifloxacin does increase the corrected QT interval.

Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans.

Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.

Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093).

P304

222-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270010391789

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Patrício Soares-da-Silva

Luis Almeida

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21415284

http://www.w3.org/2001/XMLSchema#string